Zanidatamab
Brain Metastases From HER2 and Breast Cancer
Iambic Therapeutics, Incmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Brain Metastases From HER2 and Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tucatinib Dana-Farber Cancer Institute | Phase 1 | CC |
iam1363 Iambic Therapeutics, Inc | Phase 1 | CC |
Same molecule, other indications
Zanidatamab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →